Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 103

1.

Correction: Development and validation of a novel risk score for the detection of insignificant prostate cancer in unscreened patient cohorts.

Dutto L, Ahmad A, Urbanova K, Wagner C, Schuette A, Addali M, Kelly JD, Sridhar A, Nathan S, Briggs TP, Witt JH, Shaw GL.

Br J Cancer. 2019 Apr;120(7):771. doi: 10.1038/s41416-019-0408-7.

2.

VERDICT MRI validation in fresh and fixed prostate specimens using patient-specific moulds for histological and MR alignment.

Bailey C, Bourne RM, Siow B, Johnston EW, Brizmohun Appayya M, Pye H, Heavey S, Mertzanidou T, Whitaker H, Freeman A, Patel D, Shaw GL, Sridhar A, Hawkes DJ, Punwani S, Alexander DC, Panagiotaki E.

NMR Biomed. 2019 May;32(5):e4073. doi: 10.1002/nbm.4073. Epub 2019 Feb 19.

3.

Development and validation of a novel risk score for the detection of insignificant prostate cancer in unscreened patient cohorts.

Dutto L, Ahmad A, Urbanova K, Wagner C, Schuette A, Addali M, Kelly JD, Sridhar A, Nathan S, Briggs TP, Witt JH, Shaw GL.

Br J Cancer. 2018 Dec;119(12):1445-1450. doi: 10.1038/s41416-018-0316-2. Epub 2018 Nov 27. Erratum in: Br J Cancer. 2019 Apr;120(7):771.

4.

A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer.

Warren AY, Massie CE, Watt K, Luko K, Orafidiya F, Selth LA, Mohammed H, Chohan BS, Menon S, Baridi A, Zhao W, Escriu C, Pungsrinont T, D'Santos C, Yang X, Taylor C, Qureshi A, Zecchini VR, Shaw GL, Dehm SM, Mills IG, Carroll JS, Tilley WD, McEwan IJ, Baniahmad A, Neal DE, Asim M.

Oncogene. 2019 Feb;38(7):1136-1150. doi: 10.1038/s41388-018-0501-z. Epub 2018 Sep 20.

5.

Apparatus for Histological Validation of In Vivo and Ex Vivo Magnetic Resonance Imaging of the Human Prostate.

Bourne RM, Bailey C, Johnston EW, Pye H, Heavey S, Whitaker H, Siow B, Freeman A, Shaw GL, Sridhar A, Mertzanidou T, Hawkes DJ, Alexander DC, Punwani S, Panagiotaki E.

Front Oncol. 2017 Mar 24;7:47. doi: 10.3389/fonc.2017.00047. eCollection 2017.

6.

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.

Johnston TJ, Shaw GL, Lamb AD, Parashar D, Greenberg D, Xiong T, Edwards AL, Gnanapragasam V, Holding P, Herbert P, Davis M, Mizielinsk E, Lane JA, Oxley J, Robinson M, Mason M, Staffurth J, Bollina P, Catto J, Doble A, Doherty A, Gillatt D, Kockelbergh R, Kynaston H, Prescott S, Paul A, Powell P, Rosario D, Rowe E, Donovan JL, Hamdy FC, Neal DE; ProtecT study group.

Eur Urol. 2017 Mar;71(3):381-388. doi: 10.1016/j.eururo.2016.09.040. Epub 2016 Oct 6.

7.

Whole blood mRNA in prostate cancer reveals a four-gene androgen regulated panel.

Thomas BC, Kay JD, Menon S, Vowler SL, Dawson SN, Bucklow LJ, Luxton HJ, Johnston T, Massie CE, Pugh M, Warren AY, Barker P, Burling K, Lynch AG, George A, Burge J, Corcoran M, Stearn S, Lamb AD, Sharma NL, Shaw GL, Neal DE, Whitaker HC.

Endocr Relat Cancer. 2016 Oct;23(10):797-812. doi: 10.1530/ERC-16-0287. Epub 2016 Aug 30.

PMID:
27578825
8.

Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy.

Madhu B, Shaw GL, Warren AY, Neal DE, Griffiths JR.

Metabolomics. 2016;12:120. Epub 2016 Jun 30.

9.

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.

Shaw GL, Whitaker H, Corcoran M, Dunning MJ, Luxton H, Kay J, Massie CE, Miller JL, Lamb AD, Ross-Adams H, Russell R, Nelson AW, Eldridge MD, Lynch AG, Ramos-Montoya A, Mills IG, Taylor AE, Arlt W, Shah N, Warren AY, Neal DE.

Eur Urol. 2016 Aug;70(2):214-8. doi: 10.1016/j.eururo.2015.10.042. Epub 2015 Nov 10.

10.

Late Imaging with [1-(11)C]Acetate Improves Detection of Tumor Fatty Acid Synthesis with PET.

Lewis DY, Boren J, Shaw GL, Bielik R, Ramos-Montoya A, Larkin TJ, Martins CP, Neal DE, Soloviev D, Brindle KM.

J Nucl Med. 2014 Jul;55(7):1144-9. doi: 10.2967/jnumed.113.134437. Epub 2014 Apr 28.

11.

HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network.

Ramos-Montoya A, Lamb AD, Russell R, Carroll T, Jurmeister S, Galeano-Dalmau N, Massie CE, Boren J, Bon H, Theodorou V, Vias M, Shaw GL, Sharma NL, Ross-Adams H, Scott HE, Vowler SL, Howat WJ, Warren AY, Wooster RF, Mills IG, Neal DE.

EMBO Mol Med. 2014 May;6(5):651-61. doi: 10.1002/emmm.201303581.

12.

Identification of pathologically insignificant prostate cancer is not accurate in unscreened men.

Shaw GL, Thomas BC, Dawson SN, Srivastava G, Vowler SL, Gnanapragasam VJ, Shah NC, Warren AY, Neal DE.

Br J Cancer. 2014 May 13;110(10):2405-11. doi: 10.1038/bjc.2014.192. Epub 2014 Apr 10.

13.

Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective.

Shaw GL, Hussain M, Nair R, Bycroft J, Beltran L, Green JS, Powles T, Peters JL.

Urol Int. 2012;89(1):83-8. doi: 10.1159/000338057. Epub 2012 May 16.

14.

The role of surgery in high-risk localised prostate cancer.

Gnanapragasam VJ, Mason MD, Shaw GL, Neal DE.

BJU Int. 2012 Mar;109(5):648-58. doi: 10.1111/j.1464-410X.2011.10596.x. Epub 2011 Sep 27. Review.

15.

Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing.

Vasiljević N, Wu K, Brentnall AR, Kim DC, Thorat MA, Kudahetti SC, Mao X, Xue L, Yu Y, Shaw GL, Beltran L, Lu YJ, Berney DM, Cuzick J, Lorincz AT.

Dis Markers. 2011;30(4):151-61. doi: 10.3233/DMA-2011-0790.

16.

Augmented cecal mucosa appears pink under hexylaminolevulinate "blue light" fluorescence cystoscopy.

Tuffaha H, Shaw GL, Briggs T.

J Endourol. 2010 Jun;24(6):943-4. doi: 10.1089/end.2009.0569.

PMID:
20367243
17.

Flourescence cystoscopy--how to do it.

Shaw GL, Bunce CJ.

Photodiagnosis Photodyn Ther. 2008 Dec;5(4):267-70. doi: 10.1016/j.pdpdt.2009.01.007. Epub 2009 Feb 24. Review.

PMID:
19356669
18.

Transdermal oxybutynin: a review.

Shaw GL, Patel HR.

Expert Opin Drug Metab Toxicol. 2007 Jun;3(3):435-9. Review.

PMID:
17539749
19.

Sensitivity and specificity of the blankenship FCE system's indicators of submaximal effort.

Brubaker PN, Fearon FJ, Smith SM, McKibben RJ, Alday J, Andrews SS, Clarke E, Shaw GL Jr.

J Orthop Sports Phys Ther. 2007 Apr;37(4):161-8.

PMID:
17469668
20.

International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients.

Shaw GL, Wilson P, Cuzick J, Prowse DM, Goldenberg SL, Spry NA, Oliver T.

BJU Int. 2007 May;99(5):1056-65. Epub 2007 Mar 6. Review.

Supplemental Content

Loading ...
Support Center